Literature DB >> 7174155

Pharmacokinetics of amiodarone after intravenous and oral administration.

M Anastasiou-Nana, G M Levis, S Moulopoulos.   

Abstract

Pharmacokinetic studies were conducted in four subjects who received 150 mg amiodarone i.v., in nine subjects who received 200 or 400 mg amiodarone p.o., and in four subjects who received the drug by both routes of administration. Amiodarone concentrations were determined by high pressure liquid chromatography. Aminodarone levels after i.v. administration, with one exception, declined biphasically according to a two-compartment model. The decline appeared to be monophasic after p.o. administration with one exception. Plasma levels after p.o. administration varied considerably between subjects. The biologic half-life after p.o. administration (mean 17.1 h +/- S.D.) was higher than that calculated for the second phase after i.v. administration (mean 4.3 h +/- 0.98 S.D.). Total clearance rate during the second phase was within the range 125-288 ml/min after i.v. and 114-473 ml/min after p.o. administration. The apparent volume of distribution in the central compartment after i.v. administration was found to be about 17.0 l and that calculated for the second elimination phase, 77 l, possibly indicating a concentration of the drug in the tissues. The systemic availability of amiodarone varied from 23 to 50% as determined on the basis of of the ratios of areas under p.o. and i.v. serum concentration curves for four subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7174155

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  13 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  The effect of benziodarone on the thyroid hormone levels and the pituitary-thyroid axis.

Authors:  B Xanthopoulos; D A Koutras; M A Boukis; G D Piperingos; J Kitsopanides; A Souvatzoglou; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

Review 3.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

6.  Effects of surfactants on amiodarone intestinal absorption. I. Sodium laurylsulfate.

Authors:  R V Martín-Algarra; R M Pascual-Costa; M Merino; V G Casabó
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

7.  The correlation of serum amiodarone levels with abnormalities in the metabolism of thyroxine.

Authors:  M Anastasiou-Nana; D A Koutras; G Levis; A Souvatzoglou; M A Boukis; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

8.  Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.

Authors:  Joe-Elie Salem; Maria El-Aissaoui; Margaux Alazard; Jean-Sébastien Hulot; Nadia Aissaoui; Jean-Yves Le-Heuzey; Christian Funck-Brentano; Christophe Faisy; Saik Urien
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

9.  Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.

Authors:  S J Weir; C T Ueda
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

10.  [Amiodarone therapy--behavior of serum and fatty tissue concentrations].

Authors:  B D Gonska; K P Bethge; H Wagner; K Bosse; J Köbberling; C D Quentin; H Kreuzer
Journal:  Klin Wochenschr       Date:  1986-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.